Reference List

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med. 1998;338:853-60.

2. Havlir DV, Hellmann NS, Petropoulos CJ, et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA. 2000;283:229-34.

3. Stuyver L, Wyseur A., Rombout A, et al. Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob Agents Chemother. 1997;41:284-91.

4. Eastman PS, Boyer E, Mole L, Kolber J, Urdea M, Holodniy M. Nonisotopic hybridization assay for determination of relative amounts of genotypic human immunodeficiency virus type 1 zidovudine resistance. J Clin Microbiol. 1995;33:2777-80.

5. Japour AJ, Mayers DL, Johnson VA, et al. A standardized peripheral blood mononuclear cell culture assay for the determination of drug susceptibilities of clinical human immunodeficiency virus-1 (HIV-1) isolates. Antimicrob Agents Chemother. 1993;37:1095-101.

6. Hertogs K, de Bethune MP, Miller V. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother. 1998;42:269-76.

7. Petropoulos CJ, Parkin N, Limoli K, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2000;44:920-8.

8. Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci.U.S.A. 1993;90:5653-6.

9. Schuurman R, Brambilla D, de Groot T, Boucher C. Second worldwide evaluation of HIV-1 drug resistance genotyping quality using the ENVA 2 panel [abstract 58]. Antiviral Therapy. 1999;4 (suppl 1 ).

10. Qari SH, Respess R, Weinstock H, et al. A comparative analysis of Virco Antivirogram and ViroLogic PhenoSense phenotypic assays for drug susceptibility of HIV-1 [abstract 62]. Antiviral Therapy. 2000;5 (suppl 3).

11. Harrigan PR, Hertogs K, Larder B. Worldwide variation in antiretroviral phenotypic susceptibility in untreated individuals [abstract 455]. 8th Conference on Retroviruses and Opportunistic Infections, February 4-8, 2001, Chicago, IL. 2001.

12. Lanier ER, Hellmann N, Scott J, et al. Determination of a clinically relevant phenotypic resistance "cutoff" for abacavir using the phenosense assay [abstract 254]. 8th Conference on Retroviruses and Opportunistic Infections, February 4-8, 2001, Chicago, IL. 2001.

13. Kempf D, Brun S, Rode R, et al. Identification of clinically relevant phenotypic and genotypic break-points for ABT-378/r in multiple PI-experienced, NNRTI-naive patients [abstract 89]. Antiviral Therapy. 2000;5 (suppl 3):70-1.

14. Kuritzkes D, Sevin A, Young B, et al. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine/lamivudine/ritonavir: genotypic analysis of HIV-1 isolates from ACTG 315. J Infect Dis. 2000;181:491-7.

15. Larder BA, Kemp SD, Hertogs K. Quantitative prediction of HIV-1 phenotypic drug resistance from genotypes: the virtual phenotype (VirtualPhenotype) [abstract 63] . Antiviral Therapy. 2000;5 (suppl 3):49.

16. Graham N, Peeters F, Verbiest W, Harrigan R, Larder B. The virtual phenotype is an independent predictor of clinical response [abstract 524]. 8th Conference on Retroviruses and Opportunistic Infections, February 4-8, 2001, Chicago, IL. 2001.

17. DeGruttola V, Dix L, D'Aquila R, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antiviral Therapy. 2000;5:41-8.

18. Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial. Lancet. 1999;353:2195-99.

19. Durant J, Clevenbergh P, Garraffo R, et al. Importance of protease inhibitor plasma level in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study. AIDS. 2000;14:9.

20. Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS. 2000;14:F83-93.

21. Tural C, Ruiz L, Holtzer C, et al. Utility of HIV genotyping and clinical expert advice-The Havana Trial [abstract 434]. 8th Conference on Retroviruses and Opportunistic Infections, February 4-8, 2001, Chicago, IL. 2001.

22. Cohen C, Hunt S, Sension M, et al. Phenotypic resistance testing significantly improves response to therapy (Tx): a randomized trial (VIRA 3001) [abstract 237]. 7th Conference on Retroviruses and Opportunistic Infections, January 30-February 2, 2000, San Francisco, California. 2000;[Abstract]

23. Meynard JL, Vray M, Morand-Joubert L, et al. Impact of treatment guided by phenotypic or genotypic resistance tests on the response to antiretroviral therapy: a randomized trial (NARVAL, ANRS 088) [abstract 85]. Antiviral Therapy. 2000;5 (suppl 3):67

24. Brun-Vézinet F, Race E, Descamps D, et al. Differences between genotype and phenotype in the NARVAL trail, ANRS 088 [abstract 100]. Antiviral Therapy. 2000;5 (suppl 3):78-9.

25. Kempf D, Hsu A, Jiang P, et al. Response to ritonavir (RTV) intensification in indinavir (IDV) recipients is highly correlated with virtual inhibitory quotient [abstract 523]. 8th Conference on Retroviruses and Opportunistic Infections, February 4-8, 2001, Chicago, IL. 2001.

26. Hirsch MS, Brun-Vézinet F, D'Aquila RT, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA. 2000;283:2417-26.

27. Little SJ, Routy JP, Daar ES, et al. Antiretroviral drug susceptibility and response to initial therapy among recently HIV-infected subjects in North America [abstract 756]. 8th Conference on Retroviruses and Opportunistic Infections, February 4-8, 2001, Chicago, IL. 2001.

28. Busch MP, Lee LL, Satten GA, et al. Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion:implications for screening of blood and tissue donors. Transfusion. 1995;35:91-7.

29. Ling AE, Robbins KE, Brown TM, et al. Failure of routine HIV-1 tests in a case involving transmission with preseroconversion blood components during the infectious window period. JAMA. 2000;284:210-4.

30. Kassler WJ, Haley C, Jones WK, Gerber AR, Kennedy EJ, George JR. Performance of a rapid, on-site human immunodeficiency virus antibody assay in a public health setting. J Clin Microbiol. 1995;33:2899-902.

31. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997;278:1295-300.

32. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997;278:1291-5.

33. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci.U.S.A. 1997;94:13193-7.

34. Allain JP, Laurian Y, Paul DA, et al. Long-term evaluation of HIV antigen and antibodies to p24 and gp41 in patients with hemophilia. Potential clinical importance. N Engl J Med. 1987;317:1114-21.

35. Phillips AN, Lee CA, Elford H, et al. p24 antigenemia, CD4 lymphocyte counts and the development of AIDS. AIDS. 1991;5:1217-22.

36. Fahey JL, Taylor JMG, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med. 1990;322:166-72.

37. Jackson JB, Drew J, Lin HJ, et al. Establishment of a quality assurance program for human immunodeficiency virus type 1 DNA polymerase chain reaction assays by the AIDS Clinical Trials Group. J Clin Microbiol. 1993;31:3123-8.

38. Zazzi N, Romano L, Catucci M, et al. Low human immunodeficiency virus type 1 (HIV-1) DNA burden as a major cause for failure to detect HIV-1 DNA in clinical specimens by PCR. J Clin Microbiol. 1995;33:205-8.

39. Sauviago S, Barlet V, Guettari N, et al. Standardized nested polymerase chain reaction-based assay for detection of human immunodeficiency virus type 1 DNA in whole blood lystates. J Clin Microbiol. 1993;31:1066-74.

40. Mallet F, Hebrard C, Brand D, et al. Enzyme-linked oligosorbent assays for detection of polymerase chain reaction-amplified human immunodeficiency virus type 1. J Clin Microbiol. 1993;31:144-1449.

41. Whetsell AJ, Drew JB, Milman G, et al. Comparison of three nonradioisotopic poylmerase chain reaction-based methods for detection of human immunodeficiency virus type 1. J Clin Microbiol. 1993;30:845-53.

42. Elbeik T, Charlebois ED, Nassos P, et al. Quantitative and cost comparison of ultrasensitive human immunodeficiency virus type 1 RNA viral load assays: bayer bDNA quantiplex versions 3.0 and 2.0 and Roche PCR amplicor monitor version 1.5. J Clin Microbiol. 2000;38:1113-20.

43. Lin HJ, Pedneault L, Hollinger FB. Intra-assay performance characteristics of five assays for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 1998;36:835-9.

44. Erice A, Brambilla D, Bremer J, et al. Performance characteristics of the QUANTIPLEX HIV-1 RNA 3.0 assay for detection and quantitation of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 2000;38:2837-45.

45. Bartlett J, DeMasi R, Dawson D, Hill A. Variability in repeated consecutive measurements of plasma HIV RNA in persons receiving stable nucleoside reverse transcriptase inhibitor therapy or no treatment. J Infect Dis. 1998;178:1803-5.

46. Deeks SG, Coleman RL, White R, et al. Variance of plasma human immunodeficiency virus type 1 RNA levels measured by branched DNA within and between days. J Infect Dis. 1997;176:514-7.

47. Yen-Lieberman B, Brambilla D, Jackson B, et al. Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group Virology Laboratories. J Clin Microbiol. 1996;34:2695-701.

48. Nolte FS, Boysza J, Thurmond C, Clark WS, Lennox JL. Clinical comparison of and enhanced-sensitivity branched-DNA assay and reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 1998;36:716-20.

49. Mellors JW, Kingsley LA, Rinaldo CR, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med. 1995;122:573-9.

50. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126:946-54.

51. Lyles RH, Chu C, Mellors JW, et al. Prognostic value of plasma HIV RNA in the natural history of Pneumocystis carinii pneumonia, cytomegalovirus and mycobacterium avium complex. AIDS. 1999;13:341-9.

52. Palumbo P, Raskino C, Fiscus S, et al. Virologic and immunologic response to nucleoside reverse-transcriptase inhibitor therapy among HIV-infected infants and children. J Infect Dis. 1999;179:576-83.

53. Taha ET, Kumwenda N, Hoover DR, et al. Association of HIV-1 load and CD4 lymphocyte count with mortality among untreated African children over one year of age. AIDS. 2000;14:453-9.

54. Cozzi Lepri A, Katzenstein TL, Ullum H, et al. The relative prognostic value of plasma HIV RNA levels and CD4 lymphocyte counts in advanced HIV infection. AIDS. 1998;12:1639-43.

55. Marschner IC, Collier AC, Coombs RW, et al. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis. 1998;177:40-7.

56. O'Brien WA, Hartigan PM, Daar ES, Simberkoff MS, Hamilton JD, the VA Cooperative Study Group on AIDS. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and theraputic failure. Ann Intern Med. 1997;126:939-45.

57. Coombs RW, Welles SL, Hooper C, et al. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced HIV infection. J Infect Dis. 1996;174:704-12.

58. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med. 1996;335:1091-8.

59. HIV Surrogate Marker Collaborative Group. Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate points: a meta-analysis. AIDS Res Human Retrovir. 2000;16:1123-33.

60. Grabar S, Le Moing V, Goujard C, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med. 2000;133:401-10.

61. Sebire K, McGavin K, Land S, Middleton T, Birch C. Stability of human immunodeficiency virus RNA in blood specimens as measured by a commercial PCR-based assay. J Clin Microbiol. 1998;36:493-8.

62. Dickover RE, Herman SA, Saddiq K, Wafer D, Dillon M, Bryson YJ. Optimization of specimen-handling procedures for accurate quantitation of levels of human immunodeficiency virus RNA in plasma by reverse transcriptase PCR. J Clin Microbiol. 1998;36:1070-3.

63. Stanely SK, Ostrowski MA, Justement JS, et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med. 1996;334:1222-30.

64. Sulkowski MS, Chaisson RE, Karp CL, Moore RD, Margolick J, Quinn TC. The effect of acute infectious illness on plasma HIV-1 load and the expression of serologic markers of immune activation among HIV-infected adults. J Infect Dis. 1998;178:1642-8.

65. Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. www.hivatis.org . 2-5-2001.

66. Stein DS, Korvick JA, Vermund SH. CD4+ lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: A review. J Infect Dis. 1992;165:352-63.

67. Easterbrook PJ, Emami J, Gazzard B. Rate of CD4 cell decline and prediction of survival in zidovudine-treated patients. AIDS. 1993;7:959-67.

68. Mocroft A, Devereux H, Kinloch-De Loes S, et al. Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. 14. 2000;1545.

69. Giorgi JV, Liu Z, Hultin LE, Cumberland WG, Hennessey K, Detels R. Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels results of 6 years of follow-up. J Acquir Immune Defic Syndr. 1997;6:940-12.

70. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1 specific CD4+ T cell responses associated with control of viremia. Science. 1997;278:1447-50.

71. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science. 1997;277:112-6.

72. Lederman M, Connick E, Landay A, et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS clinical trials group protocol 315. J Infect Dis. 1998;178:70-9.

73. Walker BD, Chakrabarti S, Moss B, et al. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature. 1987;328:345-8.

74. Goulder PJR, Tang Y, Brander C, et al. Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children. J Exp Med. 2000;192:1819-32.

75. Mackewicz CE, Yang LC, Lifson JD, Levy JA. Non-cytolytic CD8 T-cell anti-HIV responses in primary HIV-1 infection. Lancet. 1994;344:1671-3.

76. Para MF, Meehan P, Holden-Wiltse J, et al. ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. Antimicrob Agents Chemother. 1999;43:1373-8.

77. Buss N. Saquinavir soft gel capsule (Fortovase): pharmacokinetics and drug interactions. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL. 1998;354:[Abstract]

78. van Heeswijk RPG, Veldkamp AI, Hoetelmans R, et al. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1 -infected individuals. AIDS. 1999;13:F95-9.

79. Kakuda TN, Page LM, Henry K, et al. Concentration-controlled (CC) antiretroviral therapy with zidovudine (ZDV), lamivudine (3TC), and indinavir (IDV): pharmacokinetics (PK) and safety [abstract 368]. 6th Conference on Retroviruses and Opportunistic Infections, January 31-February 4, 1999, Chicago, IL. 1999.

80. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15:71-5.

81. Clevenbergh P, Durant J, Garraffo R, et al. Usefulness of protease inhibitor therapeutic drug monitoring? PharmAdapt: a prospective multicenter randomized controlled trial: 12 week results [abstract 260B]. 8th Conference on Retroviruses and Opportunistic Infections, February 4-8, 2001, Chicago, IL. 2001